Getting access for patients to new medications in Germany – the biggest challenges in the HTA process and how to address them: Interview with Carsten Schwenke
Today, regulatory approval doesn’t ensure anymore, that patients benefit from new therapies. As statisticians, we also need to ensure access and reimbursement for new treatments in the different markets around the world. The process to gain this access and reimbursement in Germany comes with very specific challenges. Yet, due to the large impact of Germany …